| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
NMDA receptors (selective modulator), with preferential activity at GluN2B-containing receptors. UBP710 is a selective NMDA receptor modulator that displays greater activity in potentiating GluN2B-containing receptors compared to GluN2A-containing receptors. It functions as a positive allosteric modulator via a novel mechanism.
|
|---|---|
| ln Vitro |
UBP710 is a selective NMDA receptor modulator. It displays greater activity in potentiating GluN2B-containing receptors than those containing GluN2A. This subunit selectivity is valuable for studying the distinct roles of GluN2A and GluN2B subunits in synaptic plasticity, learning, memory, and neurological disorders. The compound acts as a positive allosteric modulator via a novel mechanism. In vitro studies would evaluate its effects on NMDA receptor-mediated currents and calcium influx.
|
| ln Vivo |
In vivo effects of UBP710 have not been extensively characterized. As a selective NMDA receptor modulator with GluN2B preference, the compound may have potential applications in models of neurological and psychiatric disorders involving NMDA receptor dysfunction. GluN2B-containing NMDA receptors are implicated in synaptic plasticity, pain, depression, and neurodegenerative diseases. Detailed in vivo data are limited. The compound is primarily used as a research tool for studying NMDA receptor pharmacology and subunit-specific functions.
|
| Enzyme Assay |
NMDA receptor binding and modulation assays are performed using membranes prepared from cells expressing recombinant NMDA receptor subunits (GluN1/GluN2A or GluN1/GluN2B). Radioligand binding studies use [3H]MK-801 or [3H]CGP-39653. For allosteric modulation studies, radioligand binding is performed in the presence of varying concentrations of UBP710 to assess changes in affinity. Functional assays measure NMDA-induced calcium influx using fluorescent indicators or electrophysiological recordings (patch-clamp) to evaluate positive allosteric modulation. Test compounds are serially diluted and added to the reaction mixture. EC50 values for potentiation are determined by non-linear regression. Each concentration is tested in duplicate.
|
| Cell Assay |
Cellular NMDA receptor modulation is evaluated in HEK-293 cells transfected with GluN1/GluN2A or GluN1/GluN2B, or in primary neuronal cultures. Cells are cultured in appropriate media and treated with UBP710 at various concentrations (0.1-100 μM). NMDA-induced calcium influx is measured using fluorescent calcium indicators (Fura-2, Fluo-4). NMDA receptor currents are recorded using whole-cell patch-clamp electrophysiology. Potentiation of NMDA responses by UBP710 is quantified as a percentage increase over baseline. Cell viability is assessed using MTT or LDH assays to evaluate potential excitotoxicity. Each experiment includes NMDA receptor agonists and known allosteric modulators as controls.
|
| Animal Protocol |
In vivo studies with UBP710 would be conducted in rodent models of neurological disorders. The compound would be administered via intraperitoneal or intravenous injection. Behavioral assessments may include tests of learning and memory, pain sensitivity, and motor function. Brain tissue would be collected for receptor occupancy studies and neurochemical analysis. Sample sizes typically range from 8-12 animals per group. Detailed protocols are not publicly available.
|
| ADME/Pharmacokinetics |
Limited PK data are available. UBP710 has a molecular weight of 262.30 g/mol. Purity: typically ≥95%. Solubility: soluble in DMSO. Storage: typically at -20°C. Bioavailability, half-life, and tissue distribution data are not publicly available. The compound is primarily used as a research tool for in vitro NMDA receptor studies.
|
| Toxicity/Toxicokinetics |
Limited toxicology data are available for UBP710. As an NMDA receptor modulator with GluN2B preference, potential toxicities would depend on the extent of receptor modulation and off-target effects. Standard toxicology studies would include acute toxicity in rodents, genotoxicity screening, and evaluation of effects on the central nervous system. No clinical trials have been reported for this compound. The compound is intended for research use only.
|
| Additional Infomation |
UBP710 is also known as 9-cyclopropylphenanthrene-3-carboxylic acid and UBP-710. It is a selective NMDA receptor modulator that displays greater activity in potentiating GluN2B-containing receptors compared to GluN2A. It functions as a positive allosteric modulator via a novel mechanism for subtype-selective neurological research. No clinical trials or regulatory approvals have been reported. The compound is for research use only.
|
| Molecular Formula |
C18H14O2
|
|---|---|
| Molecular Weight |
262.31
|
| Exact Mass |
262.099
|
| CAS # |
1333111-40-2
|
| PubChem CID |
56653422
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
488.3±14.0 °C at 760 mmHg
|
| Flash Point |
217.6±14.8 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.752
|
| LogP |
5.41
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(C1C=CC2=C(C=1)C1C=CC=CC=1C(=C2)C1CC1)=O
|
| InChi Key |
OUWRRDKZWBVAHB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H14O2/c19-18(20)13-8-7-12-9-16(11-5-6-11)14-3-1-2-4-15(14)17(12)10-13/h1-4,7-11H,5-6H2,(H,19,20)
|
| Chemical Name |
9-cyclopropylphenanthrene-3-carboxylic acid
|
| Synonyms |
UBP 710; UBP-710; UBP710
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8123 mL | 19.0614 mL | 38.1228 mL | |
| 5 mM | 0.7625 mL | 3.8123 mL | 7.6246 mL | |
| 10 mM | 0.3812 mL | 1.9061 mL | 3.8123 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
